Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cortisol and inflammatory markers have been increasingly reported as abnormal at psychosis onset. The main aim of our study was to investigate the ability of these biomarkers to predict treatment response at 12 weeks follow-up in first episode psychosis. METHODS: In a longitudinal study, we collected saliva and blood samples in 68 first episode psychosis patients (and 57 controls) at baseline and assessed response to clinician-led antipsychotic treatment after 12 weeks. Moreover, we repeated biological measurements in 39 patients at the same time we assessed the response. Saliva samples were collected at multiple time points during the day to measure diurnal cortisol levels and cortisol awakening response (CAR); interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor-α, and interferon-γ (IFN-γ) levels were analyzed from serum samples. Patients were divided into Non-Responders (n = 38) and Responders (n = 30) according to the Remission symptom criteria of the Schizophrenia Working Group Consensus. RESULTS: At first onset, Non-Responders had markedly lower CAR (d = 0.6, P = .03) and higher IL-6 and IFN-γ levels (respectively, d = 1.0, P = .003 and d = 0.9, P = .02) when compared with Responders. After 12 weeks, Non-Responders show persistent lower CAR (P = .01), and higher IL-6 (P = .04) and IFN-γ (P = .05) when compared with Responders. Comparison with controls show that these abnormalities are present in both patients groups, but are more evident in Non-Responders. CONCLUSIONS: Cortisol and inflammatory biomarkers at the onset of psychosis should be considered as possible predictors of treatment response, as well as potential targets for the development of novel therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Converging lines of genetic, post-mortem, and pre-clinical evidence suggest immune dysregulation may play a role in the pathogenesis of both schizophrenia 63–67 and depression, 68, 69 and it is hypothesised that immune alterations are seen only in a proportion of these patients (immune/inflammatory subgroups) and are linked to poor treatment response. 67, 70–72”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [70]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1988) · Cited by 4,111
Pruessner, J. C., Kirschbaum, C., Meinlschmid, G., & Hellhammer, D. H. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00108-7 · Cited by 3,638
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343
Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., Day, R., & Bertelsen, A. (1992) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000904 · Cited by 1,769
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
The link between childhood trauma and depression: insights from HPA axis studies in humans
Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 1×
“48 Therefore, increased baseline inflammatory markers could be used to stratify patients in future trials evaluating the effectiveness of adjuvant anti-inflammatory treatment.”
McGuffin, P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320088015 · Cited by 1,483
Childhood maltreatment predicts adult inflammation in a life-course study
Danese, A., Pariante, C. M., Caspi, A., Taylor, A., & Poulton, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610362104 · Cited by 1,264 · cited 1×
“…and inflammatory biomarkers have also been described in association with experiences of early life trauma, both in depression and in psychosis 12,18,27,28 ; moreover, early life trauma in depression is associated with lack of treatment response, 29 although no such data are available in psychosis.”
Self-citationThe cortisol awakening response (CAR): Facts and future directions
Fries, E., Dettenborn, L., & Kirschbaum, C. (2009) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2008.03.014 · Cited by 1,188
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Brugha, T. S., & Cragg, D. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb01360.x · Cited by 883 · cited 1×
“We collected information about stressful life events that occurred in the previous 6 months using a brief life events questionnaire, 38 and we measured perceived stress in the previous month using the Perceived Stress Scale.”
Prenatal Poly(I:C) Exposure and Other Developmental Immune Activation Models in Rodent Systems
Meyer, U. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.011 · Cited by 626 · cited 1×
“18–20 Individuals suffering with psychosis show increased cytokine levels in peripheral blood and cerebrospinal fluid and both at illness onset and in later stages of the disorder.”
Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia
Walker, E., Mittal, V., & Tessner, K. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.4.022007.141248 · Cited by 615 · cited 1×
“The aims of our study were: (1) to investigate whether cortisol and inflammatory biomarkers at baseline predicted treatment response at the 12 weeks follow-up; (2) to assess if changes in these biomarkers over the first 12 weeks were associated with treatment response in the same patients; and (3) to clarify if the pu…”
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567 · cited 1×
“30,31 Fifty-seven healthy controls were recruited from the same catchment area as the patients through advertisement in local newspapers, hospitals, and job centers, as well as from existing volunteer databases.”
BackgroundSelf-citationPsychosis Screening Questionnaire
Bebbington, P., & Nayani, T. (2014) · PsycTESTS Dataset · doi:10.1037/t30040-000 · Cited by 541
Schizophrenia : manifestations, incidence and course in different cultures
Zhablenski, A. V. (1992) · Cambridge University Press eBooks · Cited by 507
Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt181 · Cited by 470
Self-citationThe stress cascade and schizophrenia: Etiology and onset
Corcoran, C., Walker, E., Huot, R., Mittal, V., Tessner, K., Kestler, L., & Malaspina, D. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007038 · Cited by 439 · cited 1×
“…treatment response: stress plays a recognized role in precipitating the onset and relapse of psychosis, and the cortisol stress response is already abnormal at psychosis onset 2–4 ; moreover, increased inflammation has been shown to predict lack of a pharmacological response in depressed patients.”
Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Self-citationInterleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388
Self-citationThe childhood experience of care and abuse questionnaire (CECA.Q): Validation in a community series
Bifulco, A., Bernazzani, O., Moran, P. M., & Jacobs, C. (2005) · British Journal of Clinical Psychology · doi:10.1348/014466505x35344 · Cited by 382
Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
Sommer, I. E., van Westrhenen, R., Begemann, M. J. H., de Witte, L. D., Leucht, S., & Kahn, R. S. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt139 · Cited by 342
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6
Lin, A., Kenis, G., Bignotti, S., Tura, G.-J.-B., De Jong, R., Bosmans, E., Pioli, R., Altamura, C., Scharpé, S., & Maes, M. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00034-6 · Cited by 321
Mondelli, V., Cattaneo, A., Murri, M. B., Di Forti, M., Handley, R., Hepgul, N., Miorelli, A., Navari, S., Papadopoulos, A. S., Aitchison, K. J., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06745 · Cited by 303
Self-citationMondelli, V., Dazzan, P., Hepgul, N., Di Forti, M., Aas, M., D'Albenzio, A., Di Nicola, M., Fisher, H., Handley, R., Marques, T. R., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.013 · Cited by 278
Self-citationBradley, A. J., & Dinan, T. G. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810385491 · Cited by 256
Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis
Tourjman, V., Kouassi, É., Koué, M.-È., Rocchetti, M., Fortin-Fournier, S., Fusar-Poli, P., & Potvin, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.011 · Cited by 224
Serum and gene expression profile of cytokines in first-episode psychosis
Di Nicola, M., Cattaneo, A., Hepgul, N., Di Forti, M., Aitchison, K. J., Janiri, L., Murray, R. M., Dazzan, P., Pariante, C. M., & Mondelli, V. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.06.010 · Cited by 217 · cited 3×
“18–20 Individuals suffering with psychosis show increased cytokine levels in peripheral blood and cerebrospinal fluid and both at illness onset and in later stages of the disorder.”
BackgroundMethodSelf-citationLeucht, S., Davis, J. M., Engel, R. R., Kane, J. M., & Wagenpfeil, S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301325 · Cited by 216
Zhang, X. Y., Zhou, D. F., Cao, L. Y., Wu, G. Y., & Shen, Y. C. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300756 · Cited by 209
Nitta, M., Kishimoto, T., Müller, N., Weiser, M., Davidson, M., Kane, J. M., & Correll, C. U. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt070 · Cited by 204
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.9.1291 · Cited by 204
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
Emsley, R., Rabinowitz, J., & Medori, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.013 · Cited by 193
Sommer, I. E., de Witte, L., Begemann, M., & Kahn, R. S. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06823 · Cited by 182
Tandon, R., Mazzara, C., DeQuardo, J., Craig, K. A., Meador-Woodruff, J. H., Goldman, R., & Greden, J. F. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90353-n · Cited by 168
Carvalho, L. A., Torre, J. P., Papadopoulos, A. S., Poon, L., Juruena, M. F., Markopoulou, K., Cleare, A. J., & Pariante, C. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.036 · Cited by 167
Self-citationChildhood Experience of Care and Abuse Questionnaire (CECA.Q)
Smith, N., Lam, D., Bifulco, A. T., & Checkley, S. (2002) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-002-0589-9 · Cited by 156
Borges, S., Gayer-Anderson, C., & Mondelli, V. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.12.025 · Cited by 153
Self-citationWhite matter integrity as a predictor of response to treatment in first episode psychosis
Reis Marques, T., Taylor, H., Chaddock, C., Dell’Acqua, F., Handley, R., Reinders, A. A. T. S., Mondelli, V., Bonaccorso, S., DiForti, M., Simmons, A., et al. (2014) · Brain · doi:10.1093/brain/awt310 · Cited by 152
Self-citationWatson, S., Gallagher, P., Porter, R. J., Smith, M. S., Herron, L. J., Bulmer, S., Young, A. H., & Ferrier, I. N. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.029 · Cited by 145 · cited 1×
“43 Therefore, future studies should investigate the role of antiglucocorticoid treatments in ameliorating psychotic symptoms and improving cognitive function, especially in those patients showing a blunted CAR and thus less likely to respond to antipsychotic treatment.”
Ciufolini, S., Dazzan, P., Kempton, M. J., Pariante, C. M., & Mondelli, V. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.09.004 · Cited by 145
Self-citationMondelli, V., Pariante, C. M., Navari, S., Aas, M., D'Albenzio, A., Di Forti, M., Handley, R., Hepgul, N., Marques, T. R., Taylor, H., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.021 · Cited by 144
Self-citationBaumeister, D., Russell, A., Pariante, C. M., & Mondelli, V. (2014) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-014-0887-z · Cited by 142
Self-citationAiello, G., Horowitz, M., Hepgul, N., Pariante, C. M., & Mondelli, V. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.05.003 · Cited by 141
Self-citationCortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis
Palaniyappan, L. K., Marques, T. R., Taylor, H., Handley, R., Mondelli, V., Bonaccorso, S., Giordano, A., McQueen, G., Forti, M. D., Simmons, A., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.203 · Cited by 126
Self-citationAas, M., Dazzan, P., Mondelli, V., Toulopoulou, T., Reichenberg, A., Di Forti, M., Fisher, H. L., Handley, R., Hepgul, N., Marques, T., et al. (2011) · Psychological Medicine · doi:10.1017/s0033291710001170 · Cited by 124
Self-citationvan Venrooij, J. A. E. M., Fluitman, S. B. A. H. A., Lijmer, J. G., Kavelaars, A., Heijnen, C. J., Westenberg, H. G. M., Kahn, R. S., & Gispen-de Wied, C. C. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq062 · Cited by 96
Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis
Belvederi Murri, M., Pariante, C. M., Dazzan, P., Hepgul, N., Papadopoulos, A. S., Zunszain, P., Di Forti, M., Murray, R. M., & Mondelli, V. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.08.013 · Cited by 93
Self-citationGarner, B., Phassouliotis, C., Phillips, L., Markulev, C., Butselaar, F., Bendall, S., Yun, Y., & McGorry, P. D. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.06.008 · Cited by 84
First-Episode Psychosis: An Inflammatory State?
Zajkowska, Z., & Mondelli, V. (2014) · Neuroimmunomodulation · doi:10.1159/000356536 · Cited by 68
Self-citationNeurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers
Breier, A. F., Wolkowitz, O. M., Doran, A. R., Bellar, S., & Pickar, D. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90050-9 · Cited by 68
Clow, A., Law, R., Evans, P., Vallence, A.-M., Hodyl, N. A., Goldsworthy, M. R., Rothwell, J. R., & Ridding, M. C. (2014) · Stress · doi:10.3109/10253890.2014.905533 · Cited by 64
Aguilar‐Valles, A., Jung, S., Poole, S., Flores, C., & Luheshi, G. N. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.11.003 · Cited by 51
The effect of childhood trauma on pharmacological treatment response in depressed inpatients
Douglas, K. M., & Porter, R. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.06.015 · Cited by 47
Chan, H., Chang, C., Chiang, S. C., Chen, J., Chen, C., Sun, H., Hwu, H., & Lai, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108096070 · Cited by 42
Cited by
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648
The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R., Owen, M. J., & Murray, R. M. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 601
Self-citationTreatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Psychoneuroimmunology of early-life stress: the hidden wounds of childhood trauma?
Danese, A., & J Lewis, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.198 · Cited by 393
“Furthermore, initial evidence suggests that elevated baseline levels of inflammation predict poor treatment response in first-episode psychosis patients (Mondelli et al, 2015).”
BackgroundPariante, C. M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.04.001 · Cited by 382
Self-citation
Metadata
- Authors
- Mondelli, V., Ciufolini, S., Belvederi Murri, M., Bonaccorso, S., Di Forti, M., Giordano, A., Marques, T. R., Zunszain, P. A., Morgan, C., Murray, R. M., Pariante, C. M., & Dazzan, P.
- Affiliations
- King's College London (GB)
- Corresponding author
- Mondelli, Valeria
- ORCID
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-31
- Volume
- 41
- Issue
- 5
- Pages
- 1162-1170
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC4535637
- OpenAlex
- W1989502746
- Cited by
- 286
- References
- 57
- Citations by year
- 2026: 17 · 2025: 16 · 2024: 26 · 2023: 36 · 2022: 22 · 2021: 32 · 2020: 35 · 2019: 30 · 2018: 23 · 2017: 27 · 2016: 18 · 2015: 4
- FWCI
- 19.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- South London and Maudsley NHS Foundation Trust
- Wellcome Trust (WT087417)
- National Institute for Health and Care Research (CL-2008-17-005)
- Academy of Medical Sciences (AMS-SGCL5-Mondelli)
- King's College London
- Medical Research Council (MR/J002739/1)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- first-episode psychosis, cortisol
- MeSH terms
- Adult, Female, Follow-Up Studies, Humans, Hydrocortisone, Inflammation, Male, Prognosis, Psychotic Disorders, Antipsychotic Agents, Biomarkers, Cytokines, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.